MRK
UBS isn’t blinking
Merck got another bullish nod, this time from UBS, which reiterated a Buy rating and kept its $145 price target on the stock. That’s a pretty loud way of saying: “We still like this one, even after a big run.”
Why it matters
Merck’s shares have already climbed 58% over the past year and are sitting close to their 52-week high of $125.14. So this isn’t about a cheap bargain-bin story anymore — it’s about whether the market still has more upside to price in if Merck’s pipeline keeps doing pipeline things.
The investor takeaway
A fresh analyst reaffirmation won’t usually send a stock into orbit by itself. But for a heavyweight like Merck, it can help keep the momentum crowd interested, especially when the company has been stacking up optimism around its drug portfolio.
Big picture: UBS is basically telling investors this isn’t a “thanks for the gains, see you later” stock. It’s more of a “maybe don’t stop paying attention just yet” situation.